The Uterine Cancer Research Program is dedicated to defining areas of research that will have maximum impact in the prevention, early diagnosis and treatment of uterine cancer. Basic science and clinical research initiatives are critical in our quest to eliminate uterine cancer. Faculty and staff are also involved in many translational research initiatives. The goal of translational research is to take a scientific breakthrough from bench to bedside, or in other words, from the lab to the patient.
At MD Anderson, findings in the laboratory are quickly translated to the clinics, offering patients access to innovative new therapies and the opportunity to participate in clinical trials not available elsewhere. Support from major federal grants and private philanthropy have fueled this progress.
Among the numerous grants we have received for research into uterine cancer is a $10 million five-year Specialized Program of Research Excellence (SPORE) grant from the National Cancer Institute.
Uterine SPORE at MD Anderson
MD Anderson Cancer Center was the first institution to successfully compete for a $10 million, five-year Specialized Programs of Research Excellence (SPORE) grant in uterine cancer from the National Cancer Institute. This grant funds basic science and clinical research in four areas: novel therapeutics and treatment, screening and prevention, predictive factors and aggressive forms of endometrial cancer. The grant also provides start-up funds for young investigators and seed money for developmental research projects in uterine cancer.